Abstract: The present application discloses a composition for use in diagnosing cancer, the composition comprising: an antibody or antigen-binding fragment thereof that specifically binds to a BAG2 polypeptide or fragment thereof.

Abstract: The present application discloses an antibody or antigen-binding fragment thereof that binds specifically to a BAG2 polypeptide or fragment thereof, and a method of treating cancer thereof.

Abstract: The present invention relates to methods for treating colorectal cancer patients comprising selecting patients who express high level of the TGF-? response signatures and co-administering TGF-? inhibitor with human immunoglobulin. The invention also relates to the method of diagnosing and selecting patients which is likely to benefit from the treatment comprising the determination of the gene expression levels of TGF-? response signature by analyzing histopathologic images of stroma or RNA sequence from the patients.

Abstract: Disclosed is a pharmaceutical composition comprising a Smad6-derived peptide as an active ingredient. Having ability to specifically bind to Pellino-1, the Smad6-derived peptide is effectively useful in the treatment of the sepsis mediated by excessively activated TLR. The peptide effectively reduces the expression of inflammatory cytokines, protects cells from sepsis-induced apoptosis, and exhibits high bacterial clearance in animal models of sepsis.

Abstract: Disclosed is a pharmaceutical composition comprising a Smad6-derived peptide as an active ingredient. Having ability to specifically bind to Pellino-1, the Smad6-derived peptide is effectively useful in the treatment of the sepsis mediated by excessively activated TLR. The peptide effectively reduces the expression of inflammatory cytokines, protects cells from sepsis-induced apoptosis, and exhibits high bacterial clearance in animal models of sepsis.

Abstract: A novel purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative, a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutical composition with an inhibitory activity against Raf kinase, containing the same as an active ingredient are provided. The purinylpyridinylamino-2,4-difluorophenyl sulfonamide derivative of the present invention effectively regulates the activity of B-Raf kinase, and thus may be useful for preventing or treating cancers induced by the over-activation of Raf kinase, especially various melanoma, colorectal cancer, prostate cancer, thyroid cancer, ovarian cancer and the like.